Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

Jul 15, 2021 4:00am EDT

XOMA Declares Quarterly Preferred Stock Dividends

Jun 21, 2021 7:30am EDT

XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting

May 21, 2021 8:00am EDT

XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events

May 06, 2021 7:30am EDT

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

May 03, 2021 7:30am EDT

XOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets

Apr 15, 2021 9:05am EDT

XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters’ Option

Apr 12, 2021 7:30am EDT

XOMA Prices $35 Million Offering of Depositary Shares

Apr 06, 2021 7:01pm EDT

XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock

Apr 05, 2021 4:05pm EDT

Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

Mar 23, 2021 8:00am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...43
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2023 XOMA Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2023 XOMA • Powered by GeneratePress
    Scroll back to top